Immunomodulatory Alpha Neutrophils (IMANs) are first-in-class, off-the-shelf neutrophil-lineage cell therapies designed to directly kill tumour cells and re-ignite anti-tumour immunity in cancer patients who progress.
 
Our upcoming first-in-human Phase 1 clinical study will assess IMANs’ safety, biodistribution, and anti-tumour activity in patients with advanced cervical and head & neck cancers.